Company Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.
Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Country | Germany |
| Founded | 1993 |
| IPO Date | Nov 4, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,952 |
| CEO | Dr. Mario Polywka DPHIL, Ph.D. |
Contact Details
Address: Essener Bogen 7 Hamburg, 2M 22419 Germany | |
| Phone | 49-40-560-810 |
| Website | evotec.com |
Stock Details
| Ticker Symbol | EVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $26.16 |
| CIK Code | 0001412558 |
| CUSIP Number | 30050E105 |
| ISIN Number | US30050E1055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mario Polywka DPHIL, Ph.D. | Interim Chief Executive Officer, Member of the Management Board and Member of the Supervisory Board |
| Dr. Werner Lanthaler M.B.A., MPA, Ph.D. | Member of Management Board |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer and Member of Management Board |
| Dr. Craig Johnstone Ph.D. | Chief Operating Officer and Member of Management Board |
| Dr. Matthias Evers Ph.D. | Chief Business Officer and Member of Management Board |
| Laetitia Rouxel | Chief Financial Officer and Member of Management Board |
| Anja Bosler | Principal Accounting Officer and Senior Vice President of Group Accounting |
| Volker Braun | Executive Vice President and Head of Global Investor Relations and ESG |
| Dr. Christian Dargel | Executive Vice President Global Head of Legal and Compliance |
| Gabriele Hansen | Senior Vice President and Head of Global Corporate Communications & Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | 6-K | Report of foreign issuer |
| Apr 23, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 3, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2023 | 6-K | Report of foreign issuer |
| Aug 29, 2023 | 6-K | Report of foreign issuer |
| Jul 27, 2023 | 6-K | Report of foreign issuer |
| Jun 21, 2023 | 6-K | Report of foreign issuer |
| Jun 20, 2023 | 6-K | Report of foreign issuer |